AbbVie kicked off 2025 with a robust first quarter, exceeding analyst expectations across key financial metrics. Total net revenues reached $13.3 billion, a $550 million outperformance, driven by strong growth in its non-Humira portfolio, which expanded 21% year-over-year. Adjusted earnings per share (EPS) came in at $2.46, surpassing the consensus estimate of $2.38 and beating the company’s own guidance by $0.10. This performance underscores AbbVie’s ability to navigate the challenging landscape of biosimilar competition while leveraging its diversified portfolio and innovative pipeline.

Signify reported a mixed Q1 2025 performance, with nominal sales of EUR 1,448 million, representing a 1.3% year-over-year decline. Comparable sales fell 2.8%, reflecting broader economic challenges, particularly in Europe. However, the company demonstrated resilience through its connected lighting segment, where installed points reached 153 million, and its consumer business, which grew 3.1% with strong demand for connected home products. Adjusted EBITA margin contracted 30 basis points to 8%, primarily due to under-absorption of fixed costs and weakness in the European Professional segment. Despite these pressures, net income rose to EUR 67 million, supported by lower restructuring costs and financial expenses. Free cash flow remained positive at EUR 40 million, underscoring the company's ability to generate cash despite top-line pressures.

Phillips 66 reported Q1 2025 earnings of $487 million, or $1.18 per share, alongside an adjusted loss of $368 million, or $0.90 per share, missing analyst estimates of -$0.723 per share. The quarter saw $187 million in operating cash flow and $716 million returned to shareholders, including $247 million in share repurchases. Despite macroeconomic headwinds in refining, renewables, and chemicals, the company made progress in turnaround programs and strategic investments, positioning itself for future growth.